STOCK TITAN

Daxor Expands Midwest Footprint with Launch of ezBVA Lab Program at Premier Kansas Academic Medical Center

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Daxor (Nasdaq: DXR) launched a commercial Blood Volume Analysis program at an academic medical center in Kansas, expanding its Midwest footprint. The program uses the company’s Tennessee-based ezBVA Lab diagnostic service, offering the health system 24-hour turnaround without upfront capital expenditure or an onsite laboratory buildout. Daxor said the model uses established reimbursement to support adoption and recurring test utilization.

Loading...
Loading translation...

Positive

  • Minor pointCommercial program launch at a Kansas academic medical center expands Daxor’s Midwest diagnostic service footprint.

Negative

  • None.

Key Figures

Diagnostic turnaround: 24 hours Upfront capital expenditure: zero
Diagnostic turnaround
24 hours
Direct blood volume diagnostics through the ezBVA Lab
Upfront capital expenditure
zero
For the Kansas health system's BVA program

Key Terms

blood volume analysis
1 terms
blood volume analysis medical
"new Blood Volume Analysis (BVA®) program"
A clinical test that measures how much blood a person has and how it is distributed between plasma and red cells, often using tracers or dyes and mathematical calculations. Think of it like measuring how much water is in different compartments of a tank to understand whether there is too much or too little; this information can affect drug dosing, treatment decisions, clinical trial endpoints, and the market value of diagnostics or therapies tied to fluid-management conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Turnkey ezBVA Lab Model Removes Capital Barriers and Leverages Established Reimbursement to Drive Rapid Clinical Adoption. 

Oak Ridge, TN, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the commercial launch of a new Blood Volume Analysis (BVA®) program at a leading academic medical center in Kansas, expanding the company’s Midwest footprint and accelerating adoption of its centralized diagnostic service.

Through Daxor’s Tennessee-based ezBVA Lab, the health system gains 24-hour turnaround on direct blood volume diagnostics with zero upfront capital expenditure or onsite laboratory buildout. This turnkey, lab-as-a-service workflow simplifies institutional onboarding and supports scalable test volume growth across clinical care teams.

“Launching our BVA program at a major academic medical center in Kansas demonstrates continued commercial momentum in the Midwest and underscores the scalability of our ezBVA Lab model,” said Annette Plishka, Senior Vice President of Commercialization at Daxor. “By removing upfront capital barriers and leveraging established reimbursement, we enable hospitals to adopt precision volume measurement rapidly, driving recurring test utilization while reducing readmissions and total cost of care.”

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Daxor launch at the Kansas academic medical center?

Daxor launched a Blood Volume Analysis program through its Tennessee-based ezBVA Lab. The service provides the health system with 24-hour diagnostic turnaround without upfront capital expenditure or an onsite laboratory buildout.

Keep reading